Perspective Therapeutics (CATX) Liabilities and Shareholders Equity (2011 - 2026)

Perspective Therapeutics has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $410.8 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $410.8 million, up 24.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 11.35% YoY), and the FY2025 annual result was $267.0 million, down 21.73% from the prior year.
• Liabilities and Shareholders Equity came in at $410.8 million for Q1 2026 at Perspective Therapeutics, up from $267.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $410.8 million in Q1 2026 to a low of $58.1 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $267.0 million (2025), against an average of $218.6 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 253.93% in 2024 and decreased 24.63% in 2025, its largest moves.
• Perspective Therapeutics' Liabilities and Shareholders Equity stood at $58.1 million in 2022, then soared by 68.51% to $97.9 million in 2023, then surged by 248.45% to $341.1 million in 2024, then slipped by 21.73% to $267.0 million in 2025, then surged by 53.86% to $410.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $410.8 million (Q1 2026), $267.0 million (Q4 2025), and $294.8 million (Q3 2025), per Business Quant data.